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Abstract
Heart failure (HF) is a highly prevalent disease state worldwide that can progress into a disabling condition. It is pertinent to have a treatment regimen that is effective in lowering
the number of HF exacerbations and, therefore, hospital readmission rates. A novel medication currently in clinical trials, LCZ696, blocks both neprilysin and angiotensin type I
receptors. The overall effects are an inhibition of the breakdown of natriuretic peptides which leads to a decrease in
renin and aldosterone release. This, combined with the
antagonization of angiotensin type I receptors, leads to a
decrease in blood pressure, blood volume and systemic vascular resistance. The PARAMOUNT trial compared the therapeutic effectiveness of LCZ696 to valsartan monotherapy.
This study demonstrated that patients taking LCZ696 had
better improvements in symptoms and biomarkers. The
PARADIGM-HF trial compared LCZ696 to enalapril. LCZ696
showed significant reductions in cardiac death, hospitalizations and HF symptoms over enalapril. Although this new
medication looks promising as a future treatment option for
HF patients, additional studies should be completed to look
at the long-term patient outcomes associated with LCZ696.
Key Terms
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Introduction
Cardiovascular disease has been the number one cause of
death in the United States almost every year since 1935. 1
Heart failure (HF), characterized by a lack of blood perfusion
due to decreased cardiac output, is a debilitating condition
worldwide. Fortunately, through extensive drug development, scientists and clinicians have been able to slow
the decline of cardiac function. Currently, angiotensinconverting-enzyme inhibitors (ACE-I) are the first line therapy options for HF patients based on recommendations from
the 2013 American College of Cardiology Foundation/
American Heart Association guidelines.2 They are effective in
preserving Left Ventricular Ejection Fraction (LVEF) and decreasing hypertension symptoms associated with HF.

However, recent research points to a novel approach in better managing HF. In clinical trials, LCZ696, a dual neprilysin
and angiotensin blocker, has consistently demonstrated clinical effectiveness in many cardiac parameters. Future studies
need to be conducted before LCZ696 is introduced into the
market and incorporated into the guidelines as an alternative
option to ACE-I, the current mainstay treatment for HF.
Epidemiology
With a prevalence of more than 5.8 million people in the
United States and 23 million people worldwide, HF is a serious public health concern.3 Each year, there are more than
550,000 new cases diagnosed in the United States
alone. Heart failure prevalence is highest among black and
Hispanic populations.2 Male and female populations have a
similar incidence and prevalence of HF. However, women
more commonly develop HF later in life and tend to survive
longer with the disease than men. Even though HF can occur
at any age, the prevalence is only about 1 to 2 percent in populations younger than 55 years of age and increases to approximately 10 percent in populations over 75 years of age.
Heart failure is a complicated clinical syndrome that is the
consequence of a structural or functional cardiac disorder. It
results in an impaired ability of the heart to pump blood sufficiently enough to meet the requirement of metabolizing
tissues.2-3 There are different types of HF which may result in
various outcomes. Left-sided HF can cause fluid backup in
the lungs resulting in shortness of breath, while right-sided
HF can cause fluid backup into the abdomen and lower extremities causing edema. 4 Heart failure can also be classified
as systolic or diastolic. Systolic HF, also known as HF with
reduced ejection fraction, occurs when the left ventricle cannot contract with enough force to pump out adequate
amounts of blood. Diastolic HF, also known as HF with preserved ejection fraction, occurs when the left ventricle does
not fill completely. Many conditions can damage the heart
resulting in HF including coronary artery disease, myocardial
infarction, hypertension, obesity, arrhythmias and other
chronic diseases such as diabetes and dyslipidemia. Following are tables of both the ACCF /AHA Stages of HF
and the New York Heart Association (NYHA) Functional Classification from the ACCF /AHA Practice Guidelines.z

Table 1. ACCF /AHA Stages of HF.2
ACCF /AHA Stages of HF

28

A

At high risk for HF with no structural heart disease or symptoms of HF

8

Structural heart disease without symptoms of HF

c

Structural heart disease with prior or current symptoms of HF

D

Refractory HF requiring specialized interventions
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Table 2. NYHA Functional Classicfication.2
NYHA Functional Classification
I
II
III

IV

No limitation of physical activity. Ordinary physical activity does not cause
HF sym ptoms
Slight limitation of physical activity. Comfortable at rest, but ordinary
physical activi ty results in HF symptoms.
Marked limitation of physical activity. Comfortable at rest, but less than
ordinary activity causes HF s ymptoms.
Unable to carry on any physical activity without symptoms of HF, or
experience HF sym ptoms at rest.

Adapted from Table 4 in the 2013 ACCF/AHA Guideline for the Management of heart failure: a report of the American
College of Cardiology Foundation/American Heart Association Task force on practice guidelines. Circ. 2013; 128: e248.

With numerous possible causes of HF, it can be difficult to
diagnose. A compilation of data from a patient's medical history, physical examination and chest radiograph along with
the presence of indicating symptoms and elevated filling
pressures are used when diagnosing HF.3 Symptoms a
patient with HF may experience include dyspnea at rest or
during exertion, fatigue or weakness, edema in the lower
extremities, tachycardia, chest pain or palpitations.2.4 When a
patient presents with these symptoms, a family history as
well as serial assessments of weight, jugular venous pressure
and vital signs should be obtained.2 Risk factors are also taken into consideration and include conditions that can damage the heart muscle. These risk factors include sleep apnea,
viral infections, obesity, alcohol or tobacco use and use of the
diabetes medications rosiglitazone and pioglitazone, which
can increase edema and worsen HF. 4 Many diagnostic tests
are used to identify the causative conditions or risk factors of
HF. One test used to distinguish between systolic and diastolic HF is an echocardiogram, which measures the ejection
fraction and produces a video image of the heart to show
how well it is pumping blood.
Hospitalization for treatment intensification is usually
required for periodic exacerbations of HF.3 Almost 1 million
hospitalizations for HF occur each year and it is the most frequent cause for hospitalization of patients over 65 years of
age. Readmission rates of HF patients <..;e 25 percent within
30 days of initial hospitalization and can reach up to SO percent within six months.2,3 Both initial hospitalization and readmission rates for HF patients continue to rise.3 It is difficult
to establish a robust risk model for readmission because
there are many factors to consider that vary from patient to
patient. 5 There are, however, some clinical predictors for
readmission. If levels of cardiac biomarkers (such as natriuretic peptides and cardiac troponins) remain high at discharge, readmission is likely.2.s Worsening renal function
during the course of hospitalization for HF is a strong predictor ofreadmission. 5 Having lower hospital readmission rates
would improve the patient's quality of life and also benefit
the hospital financially. New treatment options to help reduce hospital readmission rates are needed. One new option
is LCZ696, which targets the renin-angiotensin-aldosterone
system.
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In the renin-angiotensin-aldosterone system (also known as
RAAS), renin from the kidney is responsible for the rate
limiting step, which is the conversion of angiotensinogen. to
angiotensin I (ANG 1). 6 From this point, ANG I is converted to
angiotensin II (ANG II) via the angiotensin converting
enzyme (ACE), which is produced in the lung. Eventually,
ANG II binds to the angiotensin type 1 receptor (ATl) as seen
in Figure lA.
Figure 1A. Renin-Angiotensin-Aldosterone System.6
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Figure 18. Site of Action for Angiotensin II Receptor
Blockers.6

Once ANG II binds to its receptor, different areas of the body
are affected, including the cardiovascular system, sympathetic nervous system and pituitary gland. 6 In general, ANG II
promotes cell growth and proliferation, inflammatory response and oxidative stress. In the cardiovascular system,
ANG II causes vasoconstriction, which leads to an increase in
blood pressure and cardiac contractility. This can lead to vascular and cardiac hypertrophy. As ANG II travels to the adrenal cortex, it facilitates aldosterone secretion which helps
regulate sodium and potassium balance. These two electrolytes ultimately influence the extracellular volume. With aldosterone release, more sodium and water is reabsorbed in
the distal convoluted tubule and collecting duct. This process
promotes the excretion of potassium. ANG II also activates
the sympathetic nervous system, which promotes vasoconstriction and increases blood pressure. Furthermore, ANG II
increases vasopressin, also known as antidiuretic hormone
(ADH), which is released from the pituitary gland and increases water reabsorption. Lastly, while ANG II is activating
different systems, it also inhibits the atrial natriuretic peptide (ANP) and nitric oxide. When ANP and nitric oxide are
inhibited, the body's natural way of decreasing renin and
promoting vasodilation is prevented.
Since ANG II affects many locations in the body (especially
the heart), angiotensin II receptor blockers (ARB) are important in patients with HF. 7 As seen in Figure lB, the
mechanism of action is selective inhibition of ANG II by competitive antagonism of the ANG II receptors, more specifically
the ATl receptor. When ANG II is blocked from attaching to
the receptor, the actions mediated by ATl receptors are inhibited.6 This leads to a reduction in blood pressure by decreasing the systemic vascular resistance. The sympathetic
nervous system activity is reduced as well. There is an inhibition of aldosterone release from the adrenal gland and,
therefore, less sodium is reabsorbed when ANG II cannot
bind to the ATl receptor. While the RAAS is working, the natriuretic peptides system maintains cardiovascular homeostasis such as the vascular tone, cardiovascular remodeling
and fluid regulation.a The natriuretic peptides system is the
body's natural defense to overactive RAAS or sympathetic
nervous system. This system consists of three peptides: ANP,
B-type natriuretic peptide (BNP) and C-type natriuretic peptide
(CNP). Atrial natriuretic peptide is made in the atria and responds to atrial distention while BNP is produced in the ventricular myocytes and responds to volume overload.
C-type natriuretic peptide is secreted from the vascular
endothelium and responds to cytokines. Overall, the natriuretic
peptides system decreases the release of renin and
aldosterone, which leads to the suppression of RAAS. Due to
the suppression of RAAS, the blood pressure and blood volume
are decreased. While the sympathetic nervous system activity
is inhibited, the parasympathetic nerve activity increases.
When natriuretic peptides are released, the opposite effects of
sympathetic nervous system and RAAS occurs such as vasodilation and decrease in renin secretion (see Figure 2A).
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Neprilysin (NEP) is an enzyme that degrades the natriuretic
peptides specifically ANP and CNP.a In addition, NEP degrades ANG II, bradykinin and substance P. Bradykinin and
substance P are vasoactive peptides and are responsible for
vasodilation. One of the treatments for HF is NEP inhibitors,
as shown in Figure 2B, which increase natriuretic peptides
and allow more vasodilation to occur. Since ANG II degradation is also inhibited, there can be an increase in vasoconstriction. Therefore, NEP inhibitors depend on the balance
between the vasoconstrictor and vasodilator effects.
The angiotensin receptor neprilysin inhibitor (ARNI) may
serve as a novel treatment option for HF management and is
currently in clinical trials. 9 This drug is currently called
LCZ696 and must be taken orally in order to become activated. As seen in Figure 3, once LCZ696 is in the body, it dissociates into valsartan and Sacubitril (AHU377), which is an ARB
and a prodrug, respectively. Sacubitril (AHU377) is enzymatically cleaved into LBQ657, which is the active form of the
neprilysin inhibitor. While LBQ657 is inhibiting neprilysin,
the valsartan blocks the angiotensin type 1 receptor. Since
NEP inhibitors are dependent on the balance between the
vasoconstrictor and vasodilator effects, the valsartan blocks
any of the vasoconstrictor effects while the vasodilator
effects are activated.
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Figure 28. Site of Action of Neprilysin Inhibitors.a

Figure 2A. Role of Natriuretic Peptide Hormones.a
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ANP=atrial natriuretic peptide; BNP=B-type natriuretic peptide; CNP=C-type natriuretic peptide

Treating HF solely through the means of increasing NEP appears to be therapeutically insufficient. The ASCEND (Acute
Study of Clinical Effectiveness of Nesiritide in Decompensated HF) trial assessed nesiritide's role in the prevention of
rehospitalizations and improvements of dyspnea symptoms
in HF patients.to As a double-blind, placebo-controlled trial,
7,141 patients who were hospitalized with acute HF were
randomly assigned to either nesiritide (recombinant natriuretic peptide) or placebo for 24 to 168 hours. Nesiritide
slightly improved symptomatic dyspnea at six hours
(P=0.03) and 24 hours (P=0.007) compared to placebo. However, there was no significant difference in 30-day mortality
rate (3.6 percent with nesiritide versus 4.0 percent with placebo; absolute difference of -0.4 percentage points; 95 percent confidence interval, -1.3 to 0.5) or rates of worsening
renal function, as defined by greater than 25 percent decrease in estimated glomerular filtration rate (GFR). Additionally, nesiritide was associated with increased rates of
hypotension. Thus, the use of nesiritide should not be the
standard treatment for HF patients. Similarly, ecadotril, a
NEP inhibitor, showed little to no improvements in HF symptoms and quality oflife in a placebo-controlled trial including
279 patients. 11 Patients on ecadotril showed no difference in
the six minute walk test (6MWT) compared to placebo patients. The 6MWT is an outcome measure typically utilized in
clinical trials to assess the efficacy of HF treatments. Lastly,
ecadotril is not frequently used in practice due to its serious
side effect profile (aplastic anemia at higher doses). Candoxatril, another NEP inhibitor, was tested in 11 healthy men
and did not demonstrate a promising therapeutic option. 12
Although central venous pressure was reduced, systolic pressure was increased, most likely due to increased levels of
epinephrine and endothelin.
Spring 2015 Volume 6, Issue 2

Omapatrilat was the first combination drug manufactured to
target both neprilysin and ACE. The OVERTURE (Omapatrilat
Versus Enalapril Randomized Trial of Utility in Reducing
Events) trial compared its efficacy to an ACE-inhibitor
(enalapril) in a randomized, double-blind trial of 5,770 patients.13 The omapatrilat group demonstrated a 9 percent
lower risk of cardiovascular death or hospitalization
(P=O .024) and a 6 percent lower risk of mortality. (P=0.339).
Although showing much promise, omapatrilat does not
demonstrate a definite clinical superiority over enalapril in
reducing a primary clinical event (death and rehospitalization). Omapatrilat was shown to have a higher occurrence of
angioedema which led to its withdrawal from the market.
Angioedema most likely resulted due to increased plasma
concentrations of bradykinin. Bradykinin induces vasodilation and vascular permeability. As a result, angiotensin
receptor blockers (ARBs) were further studied as a combination product due to a decreased risk of angioedema.
LCZ696 is the first combined drug to incorporate inhibition
of neprilysin and angiotensin receptor blockade. It was extensively studied in HF with HFpEF and HF with HFrEF patients.14.ts The PARAMOUNT (Prospective Comparison of
ARNI with ARB on Management of HF with Preserved
Ejection Fraction) trial was a randomized, parallel group,
double-blind study which compared LCZ696's therapeutic
effectiveness to valsartan monotherapy.1s Patients included
in this study were required to be classified as a NYHA class II
to III (see Table 1 and Table 2), have a left ventricular
ejection fraction greater than 45 percent and have an
N-terminal B-type natriuretic peptide (NT-proBNP; marker
of ventricular wall stress) greater than 400 pg/ml. Change in
serum NT-proBNP concentrations 12 weeks from baseline
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Figure 3. Comparisons to other HF medications on the Market: Clinical Trial demonstration. 9
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was the primary endpoint in this study. Patients were then
followed through 36 weeks for additional endpoints. At the
start of the trial, 308 patients were randomized to LCZ696
200 mg twice daily or valsartan 160 mg twice daily (both
doses were bioequivalent). After 12 weeks, NT-proBNP levels were significantly reduced in the LCZ696 group compared to valsartan group (p=0.005). At 36 weeks, LCZ696
patients had better improvements in left atrial size, greater
improvements in NYHA class, and greater reductions in
blood pressure. Additionally, GFR was higher in patients receiving LCZ696 compared to patients receiving valsartan.
Further prospective studies need to be conducted in order to

32

assess whether these observed effects would translate to
improved patient outcomes. Future experiments should increase the duration of follow-up in order see the long-term
clinical benefits of LCZ696.
In the PARADIGM-HF (Prospective Comparison of ARNI with
ACE! to Determine Impact on Global Mortality and Morbidity
in HF) trial, 8,442 patients were randomly assigned to receive either LCZ696 (200 mg twice daily) or enalapril (10 mg
twice daily). 1 5 Patients were required to be classified as a
NYHA class II to III, have a left ventricular ejection fraction of
less than 40 percent and have a NT-proBNP level of greater
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than 600 pg/ml. Other inclusion criteria were GFR greater
than 30 ml/min/1.73 m2, systolic blood pressure greater
than 95 mmHg and potassium less than 5.4 mmolfl. The primary endpoint was the composite of death from cardiovascular causes or hospitalizations from HF. There were 558
deaths from cardiovascular causes in the LCZ696 patients
and 693 deaths in the enalapril patients. LCZ696 was found
to reduce hospitalizations by 21 percent and decrease symptoms and physical limitations of HF (P= 0.001). This study
ended early due to the clear and "overwhelming benefits" of
LCZ696 over enalapril.
From these clinical trials, LCZ696 has consistently demonstrated its clinical efficacy via improvements in many cardiac
parameters. Dual inhibition of neprilysin and the reninangiotensin-aldosterone system provides a new method to
effectively and safely treat HF patients.
Pharmacist Role
Although LCZ696 has been well-tolerated by patients overall,
it is still imperative that pharmacists counsel patients on the
potential side effects and the importance of adherence to
their medication regimen. A potential adverse reaction is
hypotension, so patients should be consulted about the
symptoms of low blood pressure including dizziness; syncope; blurred vision; nausea; cold, clammy, pale skin and rapid,
shallow breathing.9 Angioedema rarely occurred in trials,
but patients should be educated on signs and symptoms
so they may seek care early to avoid airway compromise. Medication noncompliance is a risk factor for hospital
admission. Counseling on the importance of HF medication
adherence helps the patients to understand why they are
taking the medication because they may not always physically feel an impact.2
It is important that pharmacists educate their patients not
only about the medications they are taking but also about
their disease states and how lifestyle modifications can impact them. Stressing the benefits of weekly physical activity,
dietary sodium and fluid restriction and staying within a
healthy weight to patients can help reduce the incidence of
HF exacerbations.2 Encouraging patients to find a support
system has been shown to reduce hospitalizations and mortality because patients are more likely to adhere to their
treatment regimen and live a healthier lifestyle. Being the
most accessible health care providers to some patients, pharmacists should follow-up with recently discharged HF
patients for education to prevent readmission and lower HF
exacerbations.s
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drug better than omapatrilat, which had higher incidence of
angioedema.13 In comparison to enalapril, LCZ696 had less
hospitalizations and less physical limitations in patients.1s
Currently, LCZ696 has been studied in patients with HFpEF;
however, longer follow-up is needed in order to determine
long-term effects of LCZ696.14 Pharmacists should be anticipating the use of this novel drug and educate patients on
ways to improve their quality of life through medications and
lifestyle modifications. Overall, pharmacists can help reduce
hospital readmission and HF exacerbations through improved patient education.s
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Conclusion/Outlook for the Future
Each year there are many new cases of HF, a disease responsible for increased hospital readmission rates. Currently,
ACE-I are used to control HF, which is insufficient alone.
A novel drug, LCZ696, may be an alternative to the current
first line therapies of ACE-I and ARB for HF, specifically
HFrEF. LCZ696 is an angiotensin receptor neprilysin inhibitor, which inhibits neprilysin through LBQ657 and blocks the
ATl receptor through valsartan.9 Overall, LCZ696 had less
cardiovascular mortality and HF hospitalizations compared
to other monotherapies. In addition, patients tolerated this
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